- Home
- XZO vs TSHA Comparison
XZO vs TSHA Comparison
Compare XZO & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XZO | TSHA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XZO | TSHA |
|---|---|---|
| Price | $17.61 | $4.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $27.00 | $10.56 |
| AVG Volume (30 Days) | 99.8K | ★ 2.6M |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 480.31 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $210,669,000.00 | $6,310,000.00 |
| Revenue This Year | $56.84 | N/A |
| Revenue Next Year | $13.24 | N/A |
| P/E Ratio | $20.25 | ★ N/A |
| Revenue Growth | ★ 138.35 | N/A |
| 52 Week Low | $12.92 | $1.05 |
| 52 Week High | $24.60 | $6.02 |
Technical Indicators
Market Signals| Indicator | XZO | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 32.47 | 45.77 |
| Support Level | $17.42 | $4.40 |
| Resistance Level | $21.25 | $4.86 |
| Average True Range (ATR) | 1.08 | 0.26 |
| MACD | -0.51 | -0.01 |
| Stochastic Oscillator | 6.12 | 30.34 |
Price Performance
Historical ComparisonAbout XZO Exzeo Group Inc.
Exzeo Group Inc provides turnkey insurance technology and operations solutions to insurance carriers and their agents based on a proprietary platform of purpose-built software and data analytics applications that are specifically designed for the property and casualty, or P&C, insurance ecosystem. Its Insurance-as-a-Service (IaaS) platform, which it refers to as the Exzeo Platform, currently includes nine configurable software and data analytics applications that are purpose-built to serve insurance companies and other customers in the insurance value chain. Through the Exzeo Platform, the company provides technology-based solutions and services for all operational and administrative activities and functions needed by P&C insurance carriers and their agents.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.